Biohaven Pharmaceutical is restructuring its global license agreement with Bristol-Myers Squibb Co. for Biohaven’s small molecule calcitonin gene-related peptide (CGRP) receptor antagonist platform, which includes rimegepant, a potential candidate for the acute treatment of migraine, and BHV-3500, a third-gen antagonist for the acute treatment and prevention of migraine. As part of the restructuring, Biohaven will pay BMS $50 million upfront in return for a reduction in royalties on sal...